pdf1 Juventas’s trial’s end-points for closing wounds on a diabetic foot not met Post published:18/01/2018
pdf1 Memorandum of Understanding for investing $500,000 in Valens in exchange for allocation of about 6.25% of preferred shares Post published:24/12/2017
pdf1 CDX signs exclusive commercialization agreement with Genomic granting a license to develop and commercialize tests for early diagnosis of prostate cancer Post published:29/11/2017
pdf1 CardiacSense completed raising funds from an external investor, after completion the company holds 7.86% Post published:05/11/2017
pdf1 Vacation of the property in Beit Shlomo completed, receiver appointed by the company will work for its sale Post published:26/10/2017
